Head-To-Head Comparison: Corvus Pharmaceuticals (NASDAQ:CRVS) vs. Adicet Bio (NASDAQ:ACET)

Corvus Pharmaceuticals (NASDAQ:CRVS) and Adicet Bio (NASDAQ:ACET) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Earnings & Valuation

This table compares Corvus Pharmaceuticals and Adicet Bio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$27.03 million	($0.93)	-4.51
Adicet Bio	$24.99 million	3.21	-$142.66 million	($1.71)	-0.57

Corvus Pharmaceuticals has higher earnings, but lower revenue than Adicet Bio. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Corvus Pharmaceuticals and Adicet Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	0	0	4	1	3.20
Adicet Bio	0	2	3	0	2.60

Corvus Pharmaceuticals currently has a consensus target price of $12.38, suggesting a potential upside of 195.35%. Adicet Bio has a consensus target price of $7.50, suggesting a potential upside of 670.50%. Given Adicet Bio’s higher probable upside, analysts clearly believe Adicet Bio is more favorable than Corvus Pharmaceuticals.

Insider & Institutional Ownership

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.9% of Adicet Bio shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 19.1% of Adicet Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Corvus Pharmaceuticals and Adicet Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-70.71%	-45.90%
Adicet Bio	N/A	-53.85%	-46.45%

Risk & Volatility

Corvus Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Adicet Bio has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500.

Summary

Corvus Pharmaceuticals beats Adicet Bio on 7 of the 13 factors compared between the two stocks.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

About Adicet Bio

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.